Publications (1)2.92 Total impact
-
Article: Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.
[show abstract] [hide abstract]
ABSTRACT: As combination of chemotherapy and Gemtuzumab may become a common induction regimen for CD33+ AML patients, there is no report assessing the safety and toxicity of a re-treatment at relapse with such combination in a same patient. Here we describe the case of a 69-year-old patient who achieved a second complete remission with this association without additional toxicity.Leukemia Research 09/2008; 32(8):1321-2. · 2.92 Impact Factor
